D. R. Budman

692 total citations
14 papers, 562 citations indexed

About

D. R. Budman is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, D. R. Budman has authored 14 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in D. R. Budman's work include HER2/EGFR in Cancer Research (4 papers), Breast Cancer Treatment Studies (3 papers) and Cancer therapeutics and mechanisms (2 papers). D. R. Budman is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Breast Cancer Treatment Studies (3 papers) and Cancer therapeutics and mechanisms (2 papers). D. R. Budman collaborates with scholars based in United States. D. R. Budman's co-authors include Larry Norton, Ann D. Thor, Donald A. Berry, I. Craig Henderson, Gloria Broadwater, Maurice Barcos, Daniel F. Hayes, Edison T. Liu, Willi Kreis and Lynn Dressler and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

D. R. Budman

14 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. R. Budman United States	8	272	261	231	91	84	14	562
M. J. Duffy Ireland	12	268 1.0×	280 1.1×	195 0.8×	33 0.4×	65 0.8×	22	650
Morihiko Kimura Japan	16	349 1.3×	191 0.7×	204 0.9×	145 1.6×	77 0.9×	47	698
B. Lisboa Germany	12	474 1.7×	203 0.8×	376 1.6×	207 2.3×	97 1.2×	23	788
In Ae Park South Korea	12	319 1.2×	186 0.7×	241 1.0×	62 0.7×	88 1.0×	18	605
Zora Nešković‐Konstantinović Serbia	14	419 1.5×	338 1.3×	144 0.6×	123 1.4×	46 0.5×	49	698
J.-M. Nabholtz Canada	9	518 1.9×	187 0.7×	209 0.9×	46 0.5×	110 1.3×	24	742
Howard Grossberg United States	8	432 1.6×	270 1.0×	125 0.5×	201 2.2×	180 2.1×	12	743
Alexandre Bodmer Switzerland	14	344 1.3×	177 0.7×	259 1.1×	123 1.4×	105 1.3×	49	692
Reinaldo Chacón Argentina	13	302 1.1×	166 0.6×	151 0.7×	79 0.9×	21 0.3×	26	580
M. Koukourakis Greece	12	227 0.8×	284 1.1×	125 0.5×	20 0.2×	96 1.1×	28	563

Countries citing papers authored by D. R. Budman

Since Specialization

Citations

This map shows the geographic impact of D. R. Budman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. R. Budman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. R. Budman more than expected).

Fields of papers citing papers by D. R. Budman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. R. Budman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. R. Budman. The network helps show where D. R. Budman may publish in the future.

Co-authorship network of co-authors of D. R. Budman

This figure shows the co-authorship network connecting the top 25 collaborators of D. R. Budman. A scholar is included among the top collaborators of D. R. Budman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. R. Budman. D. R. Budman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Oswald, Michaela, John L. Lovecchio, Houman Khalili, et al.. (2013). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. British Journal of Cancer. 110(4). 976–983. 122 indexed citations

Kritharis, Athena, Thomas Bradley, & D. R. Budman. (2011). Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL).. Journal of Clinical Oncology. 29(15_suppl). e19724–e19724. 4 indexed citations

Gralla, Richard J., et al.. (2009). Determining the preferred dose of the serotonin antagonist (5-HT3) palonosetron: Results of an individual patient data meta-analysis (MA) of 1,947 patients in all randomized double blinded (RDB) trials. Journal of Clinical Oncology. 27(15_suppl). e20512–e20512. 2 indexed citations

Dressler, Lynn G., Donald A. Berry, Gloria Broadwater, et al.. (2005). Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients. Journal of Clinical Oncology. 23(19). 4287–4297. 82 indexed citations

Budman, D. R., A H Calvert, Eric K. Rowinsky, & Bridget T. Hill. (2004). Handbook of Anticancer Drug Development. Anti-Cancer Drugs. 15(10). 1001–1001. 42 indexed citations

Berry, Donald A., Hyman B. Muss, Ann D. Thor, et al.. (2000). HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer. Journal of Clinical Oncology. 18(20). 3471–3479. 146 indexed citations

Berry, Donald A. & D. R. Budman. (1999). RESPONSE: Re: Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer. JNCI Journal of the National Cancer Institute. 91(16). 1425–1425. 1 indexed citations

Kreis, Willi, et al.. (1997). Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.. PubMed. 57(4). 714–9. 63 indexed citations

Lichtman, Stuart M., Mark J. Ratain, David A. Van Echo, et al.. (1993). Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study. JNCI Journal of the National Cancer Institute. 85(16). 1319–1326. 31 indexed citations

10.

Chan, Keith K. H., D. R. Budman, Philip Schulman, et al.. (1988). Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.. PubMed. 48(5). 1337–42. 34 indexed citations

11.

Raymond, Raymond, et al.. (1985). Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.. PubMed. 45(4). 1862–8. 17 indexed citations

12.

Budman, D. R., Philip Schulman, V. Vinciguerra, et al.. (1984). Phase I trial of vinzolidine.. PubMed. 68(7-8). 979–82. 7 indexed citations

13.

Forastiere, Arlene A., D. R. Budman, Frederick Richards, et al.. (1983). Phase II trial of aclarubicin in advanced breast cancer: a cancer and leukemia group B study.. PubMed. 67(12). 1137–8. 4 indexed citations

14.

Weiselberg, Lora, et al.. (1981). Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.. PubMed. 4(2). 195–8. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact